Neowise Biotechnology

Developer of TCR-T immune cell therapy drugs for solid tumors

placeSuzhou, Jiangsu, China calendar_todayFounded 2020 language neowisebio.com

Innovation

4 patent families — focus: Chemistry & metallurgy; filing pace active. Cited 33 times.

YearFilings
20243
20252
20261

Investor mix

8 investors on record; lead investors include Apricot Capital.

Investor typeCountShare
Venture capital450%
Bank & private debt113%
Other / undisclosed338%
Coming soon